Genenta Science S.p.A. Sponsored ADR
GNTA
Genenta Science S.p.A. Sponsored ADR is a clinical-stage biotechnology company focused on developing gene and cell therapies for solid tumors. Its lead program, Temferon, is designed to deliver therapeutic activity directly within the tumor microenvironment using hematopoietic stem cell-based technology and immune-modulating mechanisms. The company’s platform is built around targeted biologic delivery through monocytes and macrophages, supporting research across difficult-to-treat cancers such as glioblastoma and other solid tumor indications. Genenta Science S.p.A. Sponsored ADR operates within the oncology and immunotherapy space, where it contributes to advanced precision medicine approaches aimed at improving the treatment of aggressive cancers. Based in Milan, Italy, the company is part of the broader life sciences sector and focuses on current clinical development programs and proprietary therapeutic platforms.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€7M
▲ +26.7% YoY
Op. Margin
–
ROIC
-24.88%
▲ +22.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€7M
▼ -10.1% YoY
Op. Cash Flow (TTM)
-€7M
▼ -10.1% YoY
Net Debt
-€21M
Net Cash Position
Cash & Equiv.
€28M
Continue Research
Peers
Biotechnology · Pick stocks to compare with GNTA
Genenta Science S.p.A. Sponsored ADR (GNTA) in three numbers
Questions about Genenta Science S.p.A. Sponsored ADR
Is Genenta Science S.p.A. Sponsored ADR a high-quality business?
Genenta Science S.p.A. Sponsored ADR scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$21M, and its weakest is return on capital at -24.9%. The Quality tab shows every check against its target.
Does Genenta Science S.p.A. Sponsored ADR (GNTA) pay a dividend?
No. Genenta Science S.p.A. Sponsored ADR (GNTA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GNTA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.